SUPPLEMENT ARTICLE |
Los Angeles, CA
Oommen A, Lambert P, Grigg J. Lancet. 2003;362:14331438
| Purpose of the Study. |
|---|
|
|
|---|
| Study Population. |
|---|
|
|
|---|
| Methods. |
|---|
|
|
|---|
20 g/L or EPX levels of
40 g/L) or a low-primed stratum (ECP levels of <20 g/L or EPX levels of <40 g/L). Patients in the high-primed stratum were considered at high risk for developing persistent wheeze. Patients were then randomized to receive 5 days of oral prednisolone (20 mg) or placebo treatment. Parents were told to initiate medication for the next episode of viral wheezing. Parents recorded daytime and nighttime lower respiratory tract symptoms for 7 days after the initiation of trial medication. Inhaled salbutamol was administered to patients as needed, and parents were instructed to record use. The childrens physicians could substitute orally administered prednisolone if it was deemed clinically necessary. Patients who did not experience an episode of viral wheezing within 12 months after randomization were withdrawn from the study. | Results. |
|---|
|
|
|---|
| Conclusions. |
|---|
|
|
|---|
| Reviewers Comments. |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||